KTTA

Pasithea Therapeutics Corp

• TipRanks·1h ago

  Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

• Benzinga·1h ago

  Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis

• TipRanks·05/21 10:15

  Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

• Benzinga·05/15 22:22

  Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

• PUBT·05/05 20:46

  Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan

• TipRanks·05/04 23:03

  Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

• Seeking Alpha·05/04 12:34

  Pasithea Therapeutics appoints chief medical officer

• NASDAQ·05/04 11:37

  Pasithea Therapeutics Appoints Kartik Krishnan As CMO

• TipRanks·05/04 11:32

  Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

• PUBT·05/04 11:05

  Pasithea Therapeutics names Kartik Krishnan chief medical officer

• Dow Jones·05/04 11:03

  *Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

• Dow Jones·05/04 11:01

  Press Release: Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

• TipRanks·04/20 16:40

  Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Pasithea Therapeutics Corp (KTTA)

• Dow Jones·04/20 16:37

  Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

• Benzinga·04/20 16:27

  HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target